FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a double-stranded RNAi agent for inhibiting the expression of transthyretin (TTR) in a cell (variants), a pharmaceutical composition for inhibiting the expression of transthyretin (TTR), a method of inhibiting the expression of transthyretin (TTR) in a cell and a set for its implementation, a method of treating or preventing a TTR-associated disease in an individual, and a set for its implementation. In one embodiment, the double-stranded agent comprises a sense strand and an antisense strand with the following sequences of SEQ ID NO: 2211 and 2217, respectively.
EFFECT: invention expands the arsenal of agents for inhibiting the expression of transthyretin (TTR) in the cell.
58 cl, 15 dwg, 10 tbl, 51 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MIRNA STRUCTURES WITH HIGH ACTIVITY AND REDUCED EXPOSURE OUTSIDE THE TARGET | 2016 |
|
RU2788030C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2749882C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2719192C2 |
| MODIFIED OLIGONUCLEOTIDES AND METHODS OF THEIR USE | 2017 |
|
RU2802836C2 |
| DELIVERY, USE AND USE IN THERAPY OF CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETED ACTION ON DISORDERS AND DISEASES USING VIRAL COMPONENTS | 2014 |
|
RU2716421C2 |
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| RNA INTERFERENCE-MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION WITH THE USE OF A SMALL INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2745848C2 |
| NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN CELL | 2018 |
|
RU2822093C1 |
| COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
